OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Lustberg on the Real-World Use of Ovarian Suppression in HR+/HER2+ Breast Cancer

January 5th 2023

Maryam Lustberg, MD, MPH, discusses the real-world use of ovarian suppression therapy in clinical practice for premenopausal patients with hormone receptor-positive, HER2-positive breast cancer.

Dr. Kruse on the Effect of Socioeconomic Disparities on Survival Outcomes in Breast Cancer

January 5th 2023

Megan Kruse, MD, discusses how socioeconomic disparities and access to health insurance can contribute to poorer overall survival (OS) outcomes in adolescent patients with invasive breast cancer.

Dr. Alvarnas on the Importance of Access to CAR T-cell Therapy in Cancer Care

January 5th 2023

Joseph Alvarnas, MD, discusses the importance of access to CAR T-cell therapy in cancer care.

Dr. Dadwal on the Investigation of Posoleucel Following Allogeneic HCT

January 5th 2023

Sanjeet Singh Dadwal, MD, discusses the investigation of posoleucel as a prevention strategy for infections in patients following an allogenic hematopoietic cell transplant.

Dr. Zakrzewski on Investigation of IT848 Nanotherapy in Hematologic Malignancies

January 5th 2023

Johannes Zakrzewski, MD, discusses the investigation of a nanoframework-based delivery system for IT848 in hematologic malignancies.

Dr. Verschraegen on the Need for Predictive Biomarkers for Immunotherapy in Melanoma

January 4th 2023

Claire F. Verschraegen, MD, discusses the need for predictive biomarkers for the use of immunotherapy in the treatment of melanoma.

Dr. Meisel on Effect of the HER2-Low Classification Breast Cancer

January 4th 2023

Jane L. Meisel, MD, discusses the effect of the HER2-low classification for patients with breast cancer.

Dr. Dorff on Second-line Immune Checkpoint Inhibitors in Metastatic RCC

January 4th 2023

Tanya Dorff, MD, discusses remaining questions regarding sequencing in metastatic renal cell carcinoma.

Dr. Sauter on Key Considerations for Posttransplant Pembrolizumab in T-cell NHL

January 4th 2023

Craig Sauter, MD, discusses important considerations regarding the use of pembrolizumab after autologous stem cell transplant in T-cell non-Hodgkin lymphoma.

Dr. Velcheti on the Evaluation of Anti-CTLA-4 Combination Regimens in Metastatic NSCLC

January 4th 2023

Vamsidhar Velcheti, MD, discusses the evaluation of immunotherapy combination regimens for patients with metastatic non–small cell lung cancer.

Dr. Abdallah on Interim Efficacy Data on HPN217 in R/R Multiple Myeloma

December 23rd 2022

Al-Ola A. Abdallah, MD, discusses interim results from an ongoing phase 1 trial of HPN217 in heavily pretreated patients with relapsed/refractory multiple myeloma.

Dr Carlo-Stella on Updated Results on RG6234 Activity in R/R Multiple Myeloma

December 23rd 2022

Carmelo Carlo-Stella, MD, PhD, discusses updated results from a phase 1 dose-escalation study of subcutaneous and intravenous RG6234 in relapsed/refractory multiple myeloma.

Experts on Second-Line Treatment Options for EGFR TKI-Resistant NSCLC

December 23rd 2022

Balazs Halmos, MD, Martin F. Dietrich, MD, PhD, Roy S. Herbst, MD, PhD, Suresh S. Ramalingam, MD, FACP, FASCO, Mark Socinski, MD, and Heather Wakelee, MD, FASCO, discuss second-line treatment options for patients with non—small cell lung cancer who progressed on first-line EGFR-directed tyrosine kinase inhibitors.

Experts on the Evaluation of CEACAM5-Targeted Therapy in NSCLC

December 23rd 2022

Balazs Halmos, MD, Martin F. Dietrich, MD, PhD, Roy S. Herbst, MD, PhD, Suresh S. Ramalingam, MD, FACP, FASCO, Mark Socinski, MD, and Heather Wakelee, MD, FASCO, discuss the evaluation of CEACAM5 biomarker testing in non–small cell lung cancer.

Experts on the Use of ADCs in HER2-Mutated NSCLC Treatment

December 23rd 2022

Balazs Halmos, MD, Martin F. Dietrich, MD, PhD, Roy S. Herbst, MD, PhD, Suresh S. Ramalingam, MD, FACP, FASCO, Mark Socinski, MD, and Heather Wakelee, MD, FASCO, discuss the use of antibody-drug conjugates (ADCs) in HER2-mutated non–small cell lung cancer.

Dr. Tarantino on the Impact of the DESTINY-Breast04 Trial in HER2-Low Breast Cancer

December 23rd 2022

Paolo Tarantino, MD, discusses the impact of the phase 3 DESTINY-Breast04 trial in the treatment of HER2-low breast cancer.

Dr. Jabbour on the Evaluation of Olverembatinib in Ponatinib-Resistant CML and Ph+ ALL

December 23rd 2022

Elias Jabbour, MD, discusses the evaluation of olverembatinib in patients with ponatinib-resistant chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Dr. Shiller on the Role of Trastuzumab Deruxtecan in HER2+ Breast Cancer

December 23rd 2022

Michelle Shiller, DO, AP/CP, MGP, discusses the role of trastuzumab deruxtecan in patients with HER2-positive breast cancer.

Dr. Kumar on Updated Data from the MAIA Trial in Newly Diagnosed Multiple Myeloma

December 23rd 2022

Shaji Kumar, MD, discusses the updated data from the phase 3 MAIA trial in newly diagnosed multiple myeloma.

Dr. Oh on the Anemia Benefit of Pacritinib in Myelofibrosis

December 23rd 2022

Stephen T. Oh, MD, PhD, discusses the anemia benefit of pacritinib in patients with myelofibrosis.